Evaxion to present at conferences, engage with stakeholders in US, Europe, and Asia.

Evaxion, a clinical-stage TechBio company, will present data and company updates at numerous conferences in the US, Europe, and Asia during the second half of 2025. The conferences will provide opportunities for the company to engage with stakeholders, including potential partners and investors, as part of its strategy to identify potential partnerships and collaborations.

Evaxion A/S, a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, has announced its participation in numerous scientific and investor conferences across the US, Europe, and Asia during the second half of 2025. These engagements are part of the company's strategy to engage with stakeholders, including potential partners and investors, to identify opportunities for business partnerships and scientific collaborations.

The company will present data and company updates at several high-profile events, including the 19th Vaccine Congress in Kyoto, the 6th ESCMID Conference on vaccines in Lisbon, the European Society for Medical Oncology (ESMO) Congress in Amsterdam, and the Society for Immunotherapy of Cancer (SITC) in Berlin. Additionally, Evaxion will participate in conferences such as the HC Wainwright Global Investment Conference in New York, the Lake Street Best Ideas Growth Conference in New York, and the National Harbor Vaccines Summit in Washington D.C.

Birgitte Rønø, CSO and interim CEO of Evaxion, expressed excitement about the company's participation in these conferences, stating, "As a scientific and innovative company, it is very important for us to present our data and discoveries and engage with the external communities. We are excited to be invited to numerous important conferences and especially thrilled to have the two-year clinical data for our personalized cancer vaccine EVX-01 selected for oral presentation at the ESMO congress in October."

Evaxion's conference participation schedule for September to December 2025 includes:

- 19th Vaccine Congress, September 7-10, Kyoto
- HC Wainwright Global Investment Conference, September 8-10, New York
- 6th ESCMID Conference on vaccines, September 10-13, Lisbon
- Lake Street Best Ideas Growth Conference, September 12, New York
- HC Andersen seminar, September 18, Copenhagen
- Vax On Vaccines: Present and future in oncology, October 1, Milan
- BiotechX Europe, October 6-8, Basel
- World Vaccine Congress Europe, October 14-16, Amsterdam
- ESMO Congress 2025, October 17-21, Berlin
- SITC 2025, November 5-9, Berlin
- National Harbor Vaccines Summit, November 13-15, Washington D.C.
- NextGen Omics, November 13-14, Boston
- London Vaccine Conference, November 13-14, London

These conferences provide Evaxion with the opportunity to showcase its advancements in AI-Immunology™ and its pipeline of personalized cancer vaccines. The company's participation in these events underscores its commitment to transforming patients' lives through innovative and targeted treatment options.

References:
[1] https://finance.yahoo.com/news/evaxion-present-several-conferences-during-120000699.html
[2] https://www.globenewswire.com/news-release/2025/08/27/3139976/0/en/Evaxion-to-present-at-several-conferences-during-the-second-half-of-2025.html